EMEA-002269-PIP01-17-M01

Key facts

Invented name
Lynparza
Active substance
Olaparib
Therapeutic area
Oncology
Decision number
P/0250/2020
PIP number
EMEA-002269-PIP01-17-M01
Pharmaceutical form(s)
  • Capsule, hard
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (Sweden)

E-mail: paediatrics@astrazeneca.com
Tel.+46 855327591

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating